151 related articles for article (PubMed ID: 24563412)
21. We should desist using RECIST, at least in GIST.
Benjamin RS; Choi H; Macapinlac HA; Burgess MA; Patel SR; Chen LL; Podoloff DA; Charnsangavej C
J Clin Oncol; 2007 May; 25(13):1760-4. PubMed ID: 17470866
[TBL] [Abstract][Full Text] [Related]
22. SARC-CTOS imaging symposium: introduction to the problem from a clinical perspective.
Benjamin RS
Oncologist; 2008; 13 Suppl 2():1-3. PubMed ID: 18434630
[TBL] [Abstract][Full Text] [Related]
23. The 'Sentinel Node' Concept: More Questions Raised than Answers Provided?
Schlag PM
Oncologist; 1998; 3(5):VI-VII. PubMed ID: 10388128
[TBL] [Abstract][Full Text] [Related]
24. Comparison of the RECIST and EORTC PET criteria in the tumor response assessment: a pooled analysis and review.
Kim JH; Kim BJ; Jang HJ; Kim HS
Cancer Chemother Pharmacol; 2017 Oct; 80(4):729-735. PubMed ID: 28780726
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable?
Forner A; Ayuso C; Varela M; Rimola J; Hessheimer AJ; de Lope CR; Reig M; Bianchi L; Llovet JM; Bruix J
Cancer; 2009 Feb; 115(3):616-23. PubMed ID: 19117042
[TBL] [Abstract][Full Text] [Related]
26. Assessment of liver tumor response to therapy: role of quantitative imaging.
Gonzalez-Guindalini FD; Botelho MP; Harmath CB; Sandrasegaran K; Miller FH; Salem R; Yaghmai V
Radiographics; 2013 Oct; 33(6):1781-800. PubMed ID: 24108562
[TBL] [Abstract][Full Text] [Related]
27. Beyond RECIST: molecular and functional imaging techniques for evaluation of response to targeted therapy.
Desar IM; van Herpen CM; van Laarhoven HW; Barentsz JO; Oyen WJ; van der Graaf WT
Cancer Treat Rev; 2009 Jun; 35(4):309-21. PubMed ID: 19136215
[TBL] [Abstract][Full Text] [Related]
28. Stable disease is a valid end point in clinical trials.
Tolcher AW
Cancer J; 2009; 15(5):374-8. PubMed ID: 19826356
[TBL] [Abstract][Full Text] [Related]
29. Response assessment in clinical trials: implications for sarcoma clinical trial design.
Jaffe CC
Oncologist; 2008; 13 Suppl 2():14-8. PubMed ID: 18434633
[TBL] [Abstract][Full Text] [Related]
30. [RECIST and the radiologist].
Cervera Deval J
Radiologia; 2014; 56(3):193-205. PubMed ID: 22902252
[TBL] [Abstract][Full Text] [Related]
31. Change in tumor size by RECIST correlates linearly with overall survival in phase I oncology studies.
Jain RK; Lee JJ; Ng C; Hong D; Gong J; Naing A; Wheler J; Kurzrock R
J Clin Oncol; 2012 Jul; 30(21):2684-90. PubMed ID: 22689801
[TBL] [Abstract][Full Text] [Related]
32. Limitations with the response evaluation criteria in solid tumors (RECIST) guidance in disseminated pediatric malignancy.
Barnacle AM; McHugh K
Pediatr Blood Cancer; 2006 Feb; 46(2):127-34. PubMed ID: 16231313
[TBL] [Abstract][Full Text] [Related]
33. RECIST - learning from the past to build the future.
Litière S; Collette S; de Vries EG; Seymour L; Bogaerts J
Nat Rev Clin Oncol; 2017 Mar; 14(3):187-192. PubMed ID: 27995946
[TBL] [Abstract][Full Text] [Related]
34. Tumor assessment criteria in phase I trials: beyond RECIST.
Levy A; Hollebecque A; Ferté C; Koscielny S; Fernandez M; Soria JC; Massard C
J Clin Oncol; 2013 Jan; 31(3):395. PubMed ID: 23248247
[No Abstract] [Full Text] [Related]
35. QA procedures for multimodality preclinical tumor drug response testing.
Lee YC; Goins BA; Fullerton GD
Med Phys; 2010 Sep; 37(9):4806-16. PubMed ID: 20964200
[TBL] [Abstract][Full Text] [Related]
36. The evolving landscape of criteria for evaluating tumor response in the era of cancer immunotherapy: From Karnofsky to iRECIST.
Inno A; Lo Russo G; Salgarello M; Corrao G; Casolino R; Galli G; Modena A; Romano L; Pusceddu S; Greco FG; Garassino MC; Gori S
Tumori; 2018; 104(2):88-95. PubMed ID: 29714647
[TBL] [Abstract][Full Text] [Related]
37. An update on criteria for assessing tumor response to treatment.
Cruite I; Osman S; Dighe M
Curr Probl Diagn Radiol; 2013; 42(5):209-19. PubMed ID: 24070714
[TBL] [Abstract][Full Text] [Related]
38. Tumor Response Assessment for Precision Cancer Therapy: Response Evaluation Criteria in Solid Tumors and Beyond.
Nishino M
Am Soc Clin Oncol Educ Book; 2018 May; 38():1019-1029. PubMed ID: 30231378
[TBL] [Abstract][Full Text] [Related]
39. Directional inconsistency between Response Evaluation Criteria in Solid Tumors (RECIST) time to progression and response speed and depth.
Johnson K; Gomez A; Burton J; White D; Chakravarty A; Schmid A; Bottino D
Eur J Cancer; 2019 Mar; 109():196-203. PubMed ID: 30738696
[TBL] [Abstract][Full Text] [Related]
40. RECIST 1.1 for Response Evaluation Apply Not Only to Chemotherapy-Treated Patients But Also to Targeted Cancer Agents: A Pooled Database Analysis.
Litière S; Isaac G; De Vries EGE; Bogaerts J; Chen A; Dancey J; Ford R; Gwyther S; Hoekstra O; Huang E; Lin N; Liu Y; Mandrekar S; Schwartz LH; Shankar L; Therasse P; Seymour L;
J Clin Oncol; 2019 May; 37(13):1102-1110. PubMed ID: 30860949
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
